Physician profile
John C Reed
NPI 1194706531
$27,058.60
in general payments reported to CMS, 2019-2025
65 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $5,469 · 2020: $552 · 2021: $12K · 2022: $3,086 · 2023: $3,297 · 2024: $2,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,440 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,439.82 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $9,959.00 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $2,057.66 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,571.33 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk As | $1,300.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $1,263.43 | 2019-2024 | |
| Eli Lilly and Company | $1,234.57 | 2019-2023 | |
| Amgen INC. | $959.49 | 2019-2024 | Repatha, Prolia, Evenity |
| Abbott Laboratories | $730.96 | 2019-2024 | Freestyle Libre 3 |
| Insulet Corporation | $677.22 | 2019-2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $596.64 | 2021-2024 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $469.54 | 2019-2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.41 | 2019-2024 | Jardiance |
| Abbvie INC. | $389.53 | 2019-2024 | |
| Radius Health, INC. | $318.41 | 2019-2024 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $316.53 | 2019-2023 | Cycloset |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $302.61 | 2021-2023 | |
| Beta Bionics, INC. | $295.86 | 2023-2024 | Ilet Bionic Pancreas |
| Dexcom, INC. | $272.57 | 2019-2023 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $270.73 | 2021-2024 | Tirosint, Licart, Tirosint |
| Bayer Healthcare Pharmaceuticals INC. | $237.35 | 2021-2024 | |
| Esperion Therapeutics, INC. | $234.69 | 2021-2024 | Nexletol |
| Horizon Therapeutics Plc | $231.17 | 2019-2023 | Tepezza |
| Medtronic, INC. | $213.06 | 2021-2023 | Minimed 780g |
| Amarin Pharma, INC. | $194.63 | 2019-2022 | |
| Antares Pharma, INC. | $184.95 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Cequr Corporation | $174.72 | 2021-2024 | Cequr Simplicity |
| Zealand Pharma US, INC. | $169.48 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $163.18 | 2019-2023 | Unithroid |
| Janssen Pharmaceuticals, INC | $158.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $143.94 | 2019-2024 | Farxiga |
| Alexion Pharmaceuticals, INC. | $142.21 | 2019-2024 | Strensiq |
| Merck Sharp & Dohme LLC | $127.83 | 2019-2021 | |
| Medtronic Minimed, INC. | $110.14 | 2019 | |
| Pfizer INC. | $109.61 | 2019-2021 | |
| Shire North American Group INC | $102.94 | 2019 | |
| Mannkind Corporation | $91.25 | 2019-2023 | Afrezza |
| Becton, Dickinson and Company | $75.69 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $64.79 | 2022-2024 | Crysvita |
| Embecta Corp. | $61.39 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Halozyme INC | $58.13 | 2023 | |
| Recordati_rare_diseases_inc. | $56.28 | 2021-2024 | Isturisa, Signifor Lar |
| Currax Pharmaceuticals LLC | $52.15 | 2019-2021 | |
| Vivus LLC | $48.82 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $45.74 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $36.83 | 2019 | |
| Nestle Healthcare Nutrition INC. | $31.54 | 2023 | |
| Companion Medical, INC. | $31.51 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $30.65 | 2019 | |
| Acella Pharmaceuticals, LLC | $30.30 | 2023-2024 | NP Thyroid 60 |
| Amphastar Pharmaceuticals, INC. | $24.10 | 2024 | |
| Eisai INC. | $22.35 | 2019 | |
| Acerus Pharmaceuticals Corporation | $20.69 | 2022 | |
| Ascensia Diabetes Care US INC. | $19.60 | 2024 | |
| Valeritas, INC. | $19.00 | 2019 | |
| Bigfoot Biomedical INC | $18.39 | 2022 | |
| Intuity Medical INC | $17.83 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Astellas Pharma US INC | $16.09 | 2024 | Veozah |
| Endo Pharmaceuticals INC. | $15.50 | 2019 | |
| Exact Sciences Corporation | $15.48 | 2024 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $15.38 | 2023 | Adthyza |
| Amryt Pharma Holdings LTD | $13.77 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$16,220.92 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.